Table 1:

Demographic, genetic and pathologic features

Variable of interest	Left-dominant (N=25)	Right-dominant (N=16)	Symmetric (N=10)	p-value
Men %	12 (48%)	7 (44%)	4 (40%)	0.93
Education (yrs.)	16.0 (15.0, 18.0)	16.0 (15.0, 18.0)	16.5 (13.0, 18.0)	0.88
Right Handedness %	21 (84%)	12 (75%)	10 (100%)	0.25
Family history present %	4 (21.1%)	6 (50%)	1 (17%)	0.24
Race % (Caucasian)	25 (100%)	15 (94%)	10 (100%)	0.51
Age at onset (yrs.)	69.6 (62.7, 74.1)	65.6 (57.2, 72.2)	67.0 (56.1, 74.7)	0.52
Age at baseline FDG-PET (yrs.)	73.6 (65.2, 78.3)	69.7 (59.8, 74.4)	70.5 (59.1, 78.6)	0.50
Time from onset to baseline (yrs.)	3.6 (2.2, 4.5)	3.1 (2.0, 5.8)	3.4 (2.6, 4.1)	0.98
Number with longitudinal visits	18 (72%)	14 (88%)	6 (60%)	0.28
Time between baseline and last clinical visit, yrs.	4.6 (2.6, 5.8)	3.0 (1.9, 3.1)	2.3 (1.9, 3.7)	0.04
PiB Status % (pos = >1.48)	8 (32%)	4 (26.7%)	0 (0%)	0.16
Positive APOE ε4 (%)	8 (36%)	3 (20%)	0 (0%)	0.104
PATHOLOGY
	N=11	N=11	N=1
Age at death (yrs.)	78.0 (67.75, 83.0)	73.5 (64.25, 82.75)	59	0.23
PSP/CBD (%)	*8/2 (73%/18%)	5/6 (46%/54%)	0/1/ (0%/100%)	0.12
Braak Stage	3 (3, 4)	2.5 (2, 3)	4	0.03
Thal Phase	2 (1,2)	0 (0, 3)	0	0.29
FDG-PET SUVRs
Left SMA	1.41 (1.32, 1.54)	1.44 (1.35, 1.51)	1.45 (1.32, 1.52)	0.93
Right SMA	1.47 (1.38, 1.58)	1.32 (1.27, 1.41)	1.46 (1.30, 1.51)	0.003
Left Broca’s	1.48 (1.38, 1.57)	1.53 (1.43, 1.64)	1.47 (1.42, 1.62)	0.37
Right Broca’s	1.60 (1.52, 1.64)	1.55 (1.42, 1.60)	1.55 (1.45, 1.67)	0.29

Data are presented as median and interquartile range, unless otherwise indicated. Abbreviations: APOE, apolipoprotein epsilon; CBD, corticobasal degeneration; FDG, [18F]- fluorodeoxyglucose; PET, positron emission tomography; PiB, Pittsburgh Compound B; PSP, progressive supranuclear palsy; SMA, supplementary motor area; SUVR, standard uptake value ratio.

^*One additional patient did not have PSP or CBD but instead had FTLD-TDP